Novo Nordisk is pursuing a dramatic reduction in the time it takes to move new medicines from the end of final clinical trials to regulatory filing by incorporating artificial intelligence into multiple steps of its launch preparation process. John Dawber, managing director for global business services, told attendees at a Reuters summit on Friday that the Danish drugmaker has cut that interval from roughly 18 months to several months by using AI-based tools.
The company has applied AI to draft regulatory documents, to examine safety datasets and to support commercial analytics for both marketed products and candidates still in clinical development. According to Dawber, these applications have shaved months off processes that previously extended close to a year and a half.
Much of the preparatory work that underpins global launches is now carried out from Novo Nordisk’s Bengaluru center, the managing director said. The India hub contributed heavily to the recent U.S. launch of the company’s oral obesity pill, and Dawber indicated that nearly every medicine launched globally has involved work from the Bangalore facility. This represents a shift in where operational tasks for launches are concentrated within the company.
On staffing, Novo Nordisk’s global business services unit is expected to have about 4,000 employees by the end of the year. Dawber noted that an earlier goal of growing the unit to 5,000 employees by 2025 is no longer realistic, even when considering the horizon out to 2027. Instead of pursuing rapid headcount expansion, the company said it will focus hiring on specific roles tied to expanding AI-led activities.
Separately, industry forecasts cited in the discussion point to machine learning potentially halving early-stage development timelines within three to five years. While that broader prediction frames the sector outlook, Novo Nordisk’s remarks concentrate on present changes in process and organization rather than projecting outcomes beyond the company’s stated staffing and operational adjustments.
Summary: Novo Nordisk reports significant reductions in post-trial to filing timelines through AI; Bengaluru center plays an increased role in global launch preparation; the global business services unit will grow selectively rather than meet prior headcount targets.